Document is current
Any future updates will be listed below
-
Authors
Magagnoli, Joseph https://orcid.org/0000-0002-8568-0097
Cummings, Tammy H.
Ambati, Meenakshi
Sutton, S. Scott
Ambati, Jayakrishna
-
Funding
Funding for this research was provided by:
University of Virginia (Stategic investment fund)
University of South Carolina
- License Information
-
More Information
Article History
Received: 17 October 2025
Revised: 12 December 2025
Accepted: 15 December 2025
First Online: 26 December 2025
Declarations
:
: This study used de-identified administrative claims data and did not involve direct patient contact or the collection of identifiable personal information. In accordance with 45 CFR ยง46.104(d)(4), it was exempt from institutional review board (IRB) review and the requirement for informed consent.
: N/A.
: Sutton has received research grants from Boehringer Ingelheim, Coherus BioSciences, EMD Serono, Gilead, and Alexion Pharmaceuticals, all for projects unrelated to the study. Jayakrishna Ambati is a co-founder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics. All other authors declare no competing interests.
: During the preparation of this work, the authors used ChatGPT to improve the readability and language of the manuscript. After using this tool/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the published article.
